Navigation Links
Vermillion Reports Second Quarter 2012 Results
Date:8/14/2012

eriod.

As of June 30, 2012, the company's cash and cash equivalents totaled $18.3 million, as compared to $19.9 million at March 31, 2012. The company utilized $2.7 million in cash for operations in the second quarter of 2012, offset by the receipt of escrow funds during the second quarter. Management expects $2.5 million to $3.5 million in cash utilization during the third quarter of 2012.

Management Commentary
"During the second quarter, we realized solid momentum in our efforts to expand payer coverage for OVA1," said Gail S. Page, Vermillion's president and chief executive officer. "In fact, as one of the largest independent payers within the Blue Cross Blue Shield system, the addition of BCBS of Michigan alone represents a 10% increase in OVA1 covered lives in the BCBS network. The addition of BCBS Louisiana was also significant, as it demonstrated our success with influential opinion leaders, like Patricia Braly, M.D. of Covington, Louisiana, who provide valuable support for the use of OVA1 by general clinicians."

"We recently reported outstanding top-line results from OVA500, a new prospective, multi-center clinical study of OVA1 that will encourage greater payer coverage and clinical adoption. The study not only demonstrates that OVA1 has exceptional performance in detecting adnexal malignancies in a pre-referral population, it showed sensitivity and negative predictive values that met or exceeded levels reported in OVA1's pivotal trial. These outstanding results further establish the valuable clinical utility of OVA1, and especially how it can help doctors identify high-risk patients with unrivaled sensitivity so that they may refer such patients appropriately to a gynecological oncologist.

"Even more exciting, OVA1 performed exceedingly well for both pre-menopausal women at 94% sensitivity and early-stage ovarian cancer at 91% sensitivity. According to the study leader, Dr. Bristow, these results point to the possibility
'/>"/>

SOURCE Vermillion, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Vermillion Sets First Quarter 2012 Conference Call for Tuesday, May 15, 2012 at 4:30 p.m. ET
2. Vermillion Announces CEO Succession Plan
3. Vermillion PAD Intended Use Study Presented at Society for Vascular Medicine 23rd Annual Scientific Sessions
4. Vermillion Announces Positive Top-Line Results from the OVA500 Multi-Center Study Led by UC Irvine
5. Qmed, the Leading Global MedTech Industry Resource, Partners with Clarimed, to Provide the Medical Manufacturing and Healthcare Industry with FDA Reports on Adverse Events
6. Sigma-Aldrich (NASDAQ: SIAL) Reports Q1 2012 Diluted EPS of $0.96, With Diluted Adjusted EPS of $0.99. Sales Increase 5% for Q1 2012. Full Year 2012 Diluted Adjusted EPS Outlook of $3.90 to $4.05 Reaffirmed.
7. Kelyniam Global Inc. Reports Record Cranial Implant Revenues in the 1st Quarter of 2012
8. Varian Medical Systems Reports Results for Second Quarter of Fiscal Year 2012
9. Mylan Reports Q1 2012 Adjusted Diluted EPS of $0.52, an 18% Increase Over Prior Year Quarter
10. CryoLife Reports Record Quarterly Revenues in First Quarter of 2012
11. PAREXEL Reports Third Quarter Fiscal Year 2012 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... , Aug. 27, 2015  A recent study ... Knee Journal, compared the Arthrosurface HemiCAP® Wave implant, ... versus an "onlay" design implant for isolated patellofemoral ... in function and pain scores, none of the ... osteoarthritis (OA). However, 53% of the patients in ...
(Date:8/27/2015)... , Aug. 27, 2015 Biosimilars ... (BPC) applauds the U.S. Food and Drug Administration ... distinguishable name in its draft guidance issued today. ... biological products proposes distinguishable names, calling for biological ... an FDA-designated suffix. This proposal reflects the agency,s ...
(Date:8/27/2015)... -- According to a new market research report "Medical ... Bariatric ), Material (Nylon, Padded, Canvas), Usage Type (Disposable, Reusable), End ... the Medical Lifting Sling Market is poised to reach USD 706.0 ... CAGR of 11.4 % from 2015 to 2020. ... T ables and 65 F ...
Breaking Medicine Technology:Study Demonstrates Dramatic Reduction in Progression of Osteoarthritis with the Arthrosurface "Inlay" Patellofemoral Implant Design Compared to Traditional "Onlay" Implant 2Study Demonstrates Dramatic Reduction in Progression of Osteoarthritis with the Arthrosurface "Inlay" Patellofemoral Implant Design Compared to Traditional "Onlay" Implant 3Biologics Prescribers Collaborative (BPC) Statement on FDA Draft Guidance entitled "Nonproprietary Naming of Biological Products" 2Medical Lifting Sling Market Worth USD 706.0 Million by 2020 2Medical Lifting Sling Market Worth USD 706.0 Million by 2020 3Medical Lifting Sling Market Worth USD 706.0 Million by 2020 4
... 2011 Reportlinker.com announces that a new market ... Gastric Cancer - Global Drug Forecasts ... 2011 http://www.reportlinker.com/p0479813/Gastric-Cancer---Global-Drug-Forecasts-and-Treatment-Analysis-to-2020-–-Volume-I-2011.html ... Treatment Analysis to 2020 – Volume I 2011 ...
... April 12, 2011 Reportlinker.com announces that a new ... Bladder Cancer - Global Drug Forecasts and ... http://www.reportlinker.com/p0479812/Bladder-Cancer---Global-Drug-Forecasts-and-Treatment-Analysis-to-2020---Volume-1-2011.html Bladder Cancer ... - Volume 1 2011 Summary ...
Cached Medicine Technology:Reportlinker Adds Gastric Cancer - Global Drug Forecasts and Treatment Analysis to 2020 - Volume I 2011 2Reportlinker Adds Gastric Cancer - Global Drug Forecasts and Treatment Analysis to 2020 - Volume I 2011 3Reportlinker Adds Gastric Cancer - Global Drug Forecasts and Treatment Analysis to 2020 - Volume I 2011 4Reportlinker Adds Gastric Cancer - Global Drug Forecasts and Treatment Analysis to 2020 - Volume I 2011 5Reportlinker Adds Gastric Cancer - Global Drug Forecasts and Treatment Analysis to 2020 - Volume I 2011 6Reportlinker Adds Gastric Cancer - Global Drug Forecasts and Treatment Analysis to 2020 - Volume I 2011 7Reportlinker Adds Gastric Cancer - Global Drug Forecasts and Treatment Analysis to 2020 - Volume I 2011 8Reportlinker Adds Gastric Cancer - Global Drug Forecasts and Treatment Analysis to 2020 - Volume I 2011 9Reportlinker Adds Gastric Cancer - Global Drug Forecasts and Treatment Analysis to 2020 - Volume I 2011 10Reportlinker Adds Gastric Cancer - Global Drug Forecasts and Treatment Analysis to 2020 - Volume I 2011 11Reportlinker Adds Gastric Cancer - Global Drug Forecasts and Treatment Analysis to 2020 - Volume I 2011 12Reportlinker Adds Gastric Cancer - Global Drug Forecasts and Treatment Analysis to 2020 - Volume I 2011 13Reportlinker Adds Gastric Cancer - Global Drug Forecasts and Treatment Analysis to 2020 - Volume I 2011 14Reportlinker Adds Gastric Cancer - Global Drug Forecasts and Treatment Analysis to 2020 - Volume I 2011 15Reportlinker Adds Gastric Cancer - Global Drug Forecasts and Treatment Analysis to 2020 - Volume I 2011 16Reportlinker Adds Gastric Cancer - Global Drug Forecasts and Treatment Analysis to 2020 - Volume I 2011 17Reportlinker Adds Gastric Cancer - Global Drug Forecasts and Treatment Analysis to 2020 - Volume I 2011 18Reportlinker Adds Gastric Cancer - Global Drug Forecasts and Treatment Analysis to 2020 - Volume I 2011 19Reportlinker Adds Gastric Cancer - Global Drug Forecasts and Treatment Analysis to 2020 - Volume I 2011 20Reportlinker Adds Gastric Cancer - Global Drug Forecasts and Treatment Analysis to 2020 - Volume I 2011 21Reportlinker Adds Gastric Cancer - Global Drug Forecasts and Treatment Analysis to 2020 - Volume I 2011 22Reportlinker Adds Bladder Cancer - Global Drug Forecasts and Treatment Analysis to 2020 - Volume 1 2011 2Reportlinker Adds Bladder Cancer - Global Drug Forecasts and Treatment Analysis to 2020 - Volume 1 2011 3Reportlinker Adds Bladder Cancer - Global Drug Forecasts and Treatment Analysis to 2020 - Volume 1 2011 4Reportlinker Adds Bladder Cancer - Global Drug Forecasts and Treatment Analysis to 2020 - Volume 1 2011 5Reportlinker Adds Bladder Cancer - Global Drug Forecasts and Treatment Analysis to 2020 - Volume 1 2011 6Reportlinker Adds Bladder Cancer - Global Drug Forecasts and Treatment Analysis to 2020 - Volume 1 2011 7Reportlinker Adds Bladder Cancer - Global Drug Forecasts and Treatment Analysis to 2020 - Volume 1 2011 8Reportlinker Adds Bladder Cancer - Global Drug Forecasts and Treatment Analysis to 2020 - Volume 1 2011 9Reportlinker Adds Bladder Cancer - Global Drug Forecasts and Treatment Analysis to 2020 - Volume 1 2011 10Reportlinker Adds Bladder Cancer - Global Drug Forecasts and Treatment Analysis to 2020 - Volume 1 2011 11Reportlinker Adds Bladder Cancer - Global Drug Forecasts and Treatment Analysis to 2020 - Volume 1 2011 12Reportlinker Adds Bladder Cancer - Global Drug Forecasts and Treatment Analysis to 2020 - Volume 1 2011 13Reportlinker Adds Bladder Cancer - Global Drug Forecasts and Treatment Analysis to 2020 - Volume 1 2011 14Reportlinker Adds Bladder Cancer - Global Drug Forecasts and Treatment Analysis to 2020 - Volume 1 2011 15
(Date:8/30/2015)... ... August 30, 2015 , ... ... company as the new Global Communications Director for InHealth Media. Mr. Spector ... spent the last 16 years doing on-air television, producing shows, on air-radio and ...
(Date:8/30/2015)... ... August 30, 2015 , ... SonaCare Medical, LLC, the ... of prostate cancer, has announced the roll-out of its newest technology – called ... Puerto Vallarta, Mexico. , The Sonablate® technology currently in use at the San ...
(Date:8/29/2015)... ... August 29, 2015 , ... "I have been ... Place, N.Y. "I specialize in manual therapy, and my invention will provide headache ... used for additional muscle dysfunction throughout the body." , They developed THE RELIEVER ...
(Date:8/29/2015)... ... August 29, 2015 , ... Next weekend is Labor ... (which astronomically, officially ends on September 22nd this year). For IT security personnel, it ... linger on which could prove far more costly than a simple headache. , Joe ...
(Date:8/29/2015)... ... August 29, 2015 , ... ... freely market and sell Arterosil and Arterosil HP, and that all claims and ... sued Vascular Health Sciences, LLC (VHS) in the United States District Court for ...
Breaking Medicine News(10 mins):Health News:InHealth Media Appoints New Global Communications Director 2Health News:Image Fusion Technology Combines MRI and Ultrasound Images to Treat Prostate Cancer 2Health News:Inventors and InventHelp Clients Develops Tension Reliever (LGI-1951) 2Health News:Business Cyber Security – Come Out of the Summer with a Clean Slate 2Health News:Business Cyber Security – Come Out of the Summer with a Clean Slate 3Health News:Business Cyber Security – Come Out of the Summer with a Clean Slate 4
... For his outstanding contributions to entomology, Bradley Mullens ... Riverside, has been elected a fellow of the prestigious ... the world serving the professional and scientific needs of entomologists ... and only nine others were elected to this ...
... HealthDay Reporter , WEDNESDAY, July 6 (HealthDay News) -- A ... children brings forth some good news: Fewer teens are having ... dropping and deaths from injury are declining. But, the ... are using drugs, more children are living in poverty and ...
... July 7, 2011 Family doctors are reluctant to ... an influenza pandemic, mostly in an effort to protect ... El Emam the Canada Research Chair in Electronic Health ... Hospital of Eastern Ontario Research Institute recently found that ...
... sized hamstring graft in an anterior cruciate ligament (ACL) reconstruction ... according to research presented at the American Orthopaedic Society for ... "Hamstring grafts are commonly used in ACL reconstruction surgeries and ... Our research illustrated that when a patient was younger than ...
... Cancer patients with blood clots -- which occur in one ... common cause of death among cancer patients -- gain no ... (IVCF) to the anticoagulant medication fondaparinux (Arixtra), according to research ... hosted by the International Association for the Study of Lung ...
... swing in Germany, soccer fans can now rest assured that ... according to a new study by researchers at Wake Forest ... journal Research in Sports Medicine. , "Injuries are common ... at the international level," said Daryl Rosenbaum, M.D., an assistant ...
Cached Medicine News:Health News:UC Riverside faculty member elected fellow of Entomological Society of America 2Health News:Fewer U.S. Teens Having Babies, Binge Drinking: Report 2Health News:Fewer U.S. Teens Having Babies, Binge Drinking: Report 3Health News:New report explains why physicians are reluctant to share patient data 2Health News:New study: Women less likely than men to fake soccer injuries 2
... Lyphochek Fertility Control ... monitor the clinically significant ... most frequently assayed during ... Elevated hCG and hCG-Beta ...
Liquichek Spinal Fluid Control is a liquid, bilevel product designed to monitor the performance of automated and manual procedures for the analysis of proteins and other critical analytes assayed in ...
The Acceava hCG Combo test provides superior performance for the diagnosis of pregnancy with a simple procedure that provides easy to read black on white results in 3 minutes for urine or 5 minutes f...
... Nucleic Sample Preparation Platform provides flexible, automated ... platform can prepare up to 96 patient ... and one half-hours, and performs onboard quantitation ... 30 minutes each. Based on Beckman ...
Medicine Products: